Abstract
Background
Treatment for primary CNS lymphoma (PCNSL) in the elderly is associated with lower response rates and higher risks of acute and late delayed toxicity as compared to younger patients. Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile. In this study we report outcomes of a consecutive series of PCNSL elderly patients initially treated with an innovative regimen combining methotrexate and temozolomide without radiotherapy or intra-thecal chemotherapy.
Methods
Histologically confirmed newly-diagnosed PCNSL patients older than 60 years were included. An induction chemotherapy was initially given (methotrexate 3 g /m2 on days 1, 10, and 20, and temozolomide 100 mg/m2 on days 1–5). Patients achieving a partial or complete response proceeded to a maintenance phase (up to 5 monthly cycles of methotrexate 3 g/m2 on day 1, and temozolomide 100 mg/m2 days 1–5). Non-responders were treated on an individual basis.
Results
Among the 23 included patients, a complete response was observed in 55%, and disease progressed in the other 45%. Median event-free survival was 8 months, and median overall survival was 35 months. Grades 3 or 4 toxicities included nephrotoxicity in three patients, and hematotoxicity in five; no neurotoxicity has been observed to date. One patient died while on treatment from complications of intestinal obstruction.
Conclusion
Our efficacy results are comparable to other reported regimens, with the advantages of a favorable toxicity profile, and absence of intra-thecal chemotherapy. Prospective, controlled studies are warranted to confirm such results.
Similar content being viewed by others
References
DeAngelis LM (2003) Primary central nervous system lymphoma: a curable brain tumor. J Clin Oncol 21(24):4471–4473
Hoang-Xuan K, Chinot OL, Taillandier L (2003) Treatment of primary central nervous system lymphoma in the elderly. Semin Oncol 30(6 Suppl 19):53–57
Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144–3150
Omuro AM, DeAngelis LM, Yahalom J et al (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64(1):69–74
Omuro AM, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62(10):1595–1600
Bessell EM, Lopez-Guillermo A, Villa S et al (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20(1):231–236
Herrlinger U, Kuker W, Uhl M et al (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57(6):843–847
Batchelor T, Carson K, O’Neill A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 21(6):1044–1049
Omuro AM, Abrey LE (2006) Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus 21(5):E12. Available via http://www.aans.org/education/journal/neurosurgical/Nov06/21–15–12-1063.pdf
Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19(3):742–749
Montemurro M, Kiefer T, Schuler F et al (2006) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol (in press), DOI 10.1093/annonc/mdl1458
Colombat P, Lemevel A, Bertrand P et al (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38(6):417–420
Illerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24(24):3865–3870
Pels H, Schmidt-Wolf IGH, Glasmacher A et al (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21(24):4489–4495
Reni M, Ferreri AJ, Landoni C et al (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92(7):575–576
Strik HM, Spreer A, Nagel H et al (2004) Clinical response following adjuvant temozolomide in a patient with primary cerebral lymphoma. Anticancer Res 24(6):4121–4125
Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40(11):1682–1688
Herrlinger U, Kuker W, Platten M et al (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58(10):1573–1574
Lerro KA, Lacy J (2002) Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59(2):165–168
Abrey LE, Batchelor TT, Ferreri AJM et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043
Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol 24(36):5711–5715
Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272
Juergens A, Pels H, Schlegel U et al (2006) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy- final report. J Neurol 253(Suppl 2)II:23–24
Hoang-Xuan K, Taillandier L, Chinot O et al (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21(14):2726–2731
Jahnke K, Korfel A, Martus P et al (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3):445–449
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
Acknowledgements
Authors thank Julie Lejeune, Celine Bequet-Boucard, Florence Laigle, Veronique Leblond, Carole Soussain, Antony Behin, Marc Sanson, Antoine Carpentier and Jean-Yves Delattre for their precious help at various stages of this study. Dr Omuro, Dr Chinot and Dr Hoang-Xuan have received honoraria from Schering-Plough for speaking and serving as scientific advisors. The study was partially funded by the Association pour la Recherche sur les Tumeurs Cerebrales (ARTC). This study was partially presented at the 58th Annual Meeting of the American Academy of Neurology, 2006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Omuro, A.M.P., Taillandier, L., Chinot, O. et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85, 207–211 (2007). https://doi.org/10.1007/s11060-007-9397-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-007-9397-0